nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—ALDH2—esophageal cancer	0.0108	0.0582	CbGpPWpGaD
Methylphenidate—SLC6A3—Alpha-synuclein signaling—UCHL1—esophageal cancer	0.00639	0.0343	CbGpPWpGaD
Methylphenidate—SLC6A3—Alpha-synuclein signaling—FKBP1A—esophageal cancer	0.00608	0.0326	CbGpPWpGaD
Methylphenidate—CYP2D6—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.00597	0.032	CbGpPWpGaD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—UCHL1—esophageal cancer	0.00543	0.0291	CbGpPWpGaD
Methylphenidate—CYP2D6—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.00472	0.0253	CbGpPWpGaD
Methylphenidate—CYP2D6—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.00414	0.0222	CbGpPWpGaD
Methylphenidate—SLC6A3—Dopaminergic Neurogenesis—SOX2—esophageal cancer	0.00412	0.0221	CbGpPWpGaD
Methylphenidate—CYP2D6—CYP2E1 reactions—CYP2A6—esophageal cancer	0.0037	0.0199	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—ALDH3A1—esophageal cancer	0.0035	0.0188	CbGpPWpGaD
Methylphenidate—CYP2D6—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00317	0.017	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—BLVRB—esophageal cancer	0.00312	0.0167	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—ALDH3A1—esophageal cancer	0.00301	0.0162	CbGpPWpGaD
Methylphenidate—CYP2D6—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00292	0.0156	CbGpPWpGaD
Methylphenidate—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A6—esophageal cancer	0.00282	0.0151	CbGpPWpGaD
Methylphenidate—CYP2D6—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.00274	0.0147	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—BLVRB—esophageal cancer	0.00268	0.0144	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—ALDH3A1—esophageal cancer	0.00267	0.0143	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—PRDX1—esophageal cancer	0.00265	0.0142	CbGpPWpGaD
Methylphenidate—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—esophageal cancer	0.00258	0.0138	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—ADCYAP1—esophageal cancer	0.00252	0.0135	CbGpPWpGaD
Methylphenidate—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A6—esophageal cancer	0.0025	0.0134	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—BLVRB—esophageal cancer	0.00238	0.0128	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—SLC39A6—esophageal cancer	0.00237	0.0127	CbGpPWpGaD
Methylphenidate—CYP2D6—Xenobiotics—CYP2A6—esophageal cancer	0.00229	0.0123	CbGpPWpGaD
Methylphenidate—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—esophageal cancer	0.00229	0.0123	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—PRDX1—esophageal cancer	0.00228	0.0122	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—ADH7—esophageal cancer	0.00226	0.0121	CbGpPWpGaD
Methylphenidate—CYP2D6—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00221	0.0118	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—CRTC1—esophageal cancer	0.00205	0.011	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—SLC39A6—esophageal cancer	0.00203	0.0109	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—PRDX1—esophageal cancer	0.00202	0.0108	CbGpPWpGaD
Methylphenidate—Ecchymosis—Methotrexate—esophageal cancer	0.00195	0.00239	CcSEcCtD
Methylphenidate—Neoplasm—Methotrexate—esophageal cancer	0.00195	0.00239	CcSEcCtD
Methylphenidate—Urinary tract disorder—Cisplatin—esophageal cancer	0.00194	0.00239	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—ADH7—esophageal cancer	0.00194	0.0104	CbGpPWpGaD
Methylphenidate—Liver function test abnormal—Capecitabine—esophageal cancer	0.00194	0.00238	CcSEcCtD
Methylphenidate—Connective tissue disorder—Cisplatin—esophageal cancer	0.00194	0.00238	CcSEcCtD
Methylphenidate—Urethral disorder—Cisplatin—esophageal cancer	0.00193	0.00237	CcSEcCtD
Methylphenidate—Gynaecomastia—Methotrexate—esophageal cancer	0.00193	0.00237	CcSEcCtD
Methylphenidate—Abdominal pain upper—Capecitabine—esophageal cancer	0.00192	0.00236	CcSEcCtD
Methylphenidate—Visual impairment—Cisplatin—esophageal cancer	0.0019	0.00233	CcSEcCtD
Methylphenidate—Breast disorder—Capecitabine—esophageal cancer	0.0019	0.00233	CcSEcCtD
Methylphenidate—Nasopharyngitis—Capecitabine—esophageal cancer	0.00188	0.00231	CcSEcCtD
Methylphenidate—Gastritis—Capecitabine—esophageal cancer	0.00186	0.00228	CcSEcCtD
Methylphenidate—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00185	0.00227	CcSEcCtD
Methylphenidate—Eye disorder—Cisplatin—esophageal cancer	0.00184	0.00226	CcSEcCtD
Methylphenidate—Lymphadenopathy—Methotrexate—esophageal cancer	0.00183	0.00225	CcSEcCtD
Methylphenidate—Flushing—Cisplatin—esophageal cancer	0.00183	0.00225	CcSEcCtD
Methylphenidate—Cardiac disorder—Cisplatin—esophageal cancer	0.00183	0.00225	CcSEcCtD
Methylphenidate—Influenza—Capecitabine—esophageal cancer	0.00181	0.00223	CcSEcCtD
Methylphenidate—Asthma—Capecitabine—esophageal cancer	0.00181	0.00223	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—SLC39A6—esophageal cancer	0.0018	0.00967	CbGpPWpGaD
Methylphenidate—Diabetes mellitus—Methotrexate—esophageal cancer	0.0018	0.00221	CcSEcCtD
Methylphenidate—Photosensitivity—Methotrexate—esophageal cancer	0.00178	0.00219	CcSEcCtD
Methylphenidate—Immune system disorder—Cisplatin—esophageal cancer	0.00178	0.00219	CcSEcCtD
Methylphenidate—CYP2D6—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00178	0.00954	CbGpPWpGaD
Methylphenidate—Mediastinal disorder—Cisplatin—esophageal cancer	0.00177	0.00218	CcSEcCtD
Methylphenidate—Angina pectoris—Capecitabine—esophageal cancer	0.00177	0.00217	CcSEcCtD
Methylphenidate—Arrhythmia—Cisplatin—esophageal cancer	0.00176	0.00216	CcSEcCtD
Methylphenidate—Bronchitis—Capecitabine—esophageal cancer	0.00174	0.00214	CcSEcCtD
Methylphenidate—Alopecia—Cisplatin—esophageal cancer	0.00174	0.00214	CcSEcCtD
Methylphenidate—Abdominal discomfort—Capecitabine—esophageal cancer	0.00174	0.00214	CcSEcCtD
Methylphenidate—Pancytopenia—Capecitabine—esophageal cancer	0.00172	0.00212	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—ADH7—esophageal cancer	0.00172	0.00922	CbGpPWpGaD
Methylphenidate—Erythema—Cisplatin—esophageal cancer	0.00171	0.00211	CcSEcCtD
Methylphenidate—Malnutrition—Cisplatin—esophageal cancer	0.00171	0.00211	CcSEcCtD
Methylphenidate—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00169	0.00207	CcSEcCtD
Methylphenidate—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.00166	0.00203	CcSEcCtD
Methylphenidate—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00166	0.00203	CcSEcCtD
Methylphenidate—Weight increased—Capecitabine—esophageal cancer	0.00165	0.00203	CcSEcCtD
Methylphenidate—Visual disturbance—Methotrexate—esophageal cancer	0.00165	0.00203	CcSEcCtD
Methylphenidate—Muscle spasms—Cisplatin—esophageal cancer	0.00165	0.00203	CcSEcCtD
Methylphenidate—Weight decreased—Capecitabine—esophageal cancer	0.00164	0.00202	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—ABCC2—esophageal cancer	0.00164	0.00879	CbGpPWpGaD
Methylphenidate—Pneumonia—Capecitabine—esophageal cancer	0.00163	0.002	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—RUNX3—esophageal cancer	0.00162	0.0087	CbGpPWpGaD
Methylphenidate—Infestation NOS—Capecitabine—esophageal cancer	0.00162	0.00199	CcSEcCtD
Methylphenidate—Infestation—Capecitabine—esophageal cancer	0.00162	0.00199	CcSEcCtD
Methylphenidate—Vision blurred—Cisplatin—esophageal cancer	0.00162	0.00199	CcSEcCtD
Methylphenidate—Depression—Capecitabine—esophageal cancer	0.00161	0.00198	CcSEcCtD
Methylphenidate—Tremor—Cisplatin—esophageal cancer	0.00161	0.00197	CcSEcCtD
Methylphenidate—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.0016	0.00197	CcSEcCtD
Methylphenidate—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00159	0.00196	CcSEcCtD
Methylphenidate—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00159	0.00196	CcSEcCtD
Methylphenidate—Lethargy—Methotrexate—esophageal cancer	0.00159	0.00196	CcSEcCtD
Methylphenidate—Ill-defined disorder—Cisplatin—esophageal cancer	0.00159	0.00195	CcSEcCtD
Methylphenidate—Myocardial infarction—Capecitabine—esophageal cancer	0.00158	0.00195	CcSEcCtD
Methylphenidate—Anaemia—Cisplatin—esophageal cancer	0.00158	0.00195	CcSEcCtD
Methylphenidate—Conjunctivitis—Capecitabine—esophageal cancer	0.00157	0.00193	CcSEcCtD
Methylphenidate—Malaise—Cisplatin—esophageal cancer	0.00155	0.0019	CcSEcCtD
Methylphenidate—Haematuria—Capecitabine—esophageal cancer	0.00154	0.00189	CcSEcCtD
Methylphenidate—Leukopenia—Cisplatin—esophageal cancer	0.00153	0.00189	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00153	0.00188	CcSEcCtD
Methylphenidate—Epistaxis—Capecitabine—esophageal cancer	0.00153	0.00187	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—NFE2L2—esophageal cancer	0.00152	0.00818	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—GAPDH—esophageal cancer	0.0015	0.00803	CbGpPWpGaD
Methylphenidate—Irritability—Methotrexate—esophageal cancer	0.00149	0.00183	CcSEcCtD
Methylphenidate—Convulsion—Cisplatin—esophageal cancer	0.00149	0.00183	CcSEcCtD
Methylphenidate—Mood swings—Methotrexate—esophageal cancer	0.00148	0.00182	CcSEcCtD
Methylphenidate—Bradycardia—Capecitabine—esophageal cancer	0.00148	0.00182	CcSEcCtD
Methylphenidate—Myalgia—Cisplatin—esophageal cancer	0.00146	0.00179	CcSEcCtD
Methylphenidate—Haemoglobin—Capecitabine—esophageal cancer	0.00146	0.00179	CcSEcCtD
Methylphenidate—Rhinitis—Capecitabine—esophageal cancer	0.00146	0.00179	CcSEcCtD
Methylphenidate—Anxiety—Cisplatin—esophageal cancer	0.00145	0.00179	CcSEcCtD
Methylphenidate—Haemorrhage—Capecitabine—esophageal cancer	0.00145	0.00178	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00145	0.00178	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—SOX2—esophageal cancer	0.00145	0.00775	CbGpPWpGaD
Methylphenidate—Liver function test abnormal—Methotrexate—esophageal cancer	0.00144	0.00177	CcSEcCtD
Methylphenidate—Discomfort—Cisplatin—esophageal cancer	0.00144	0.00177	CcSEcCtD
Methylphenidate—Pharyngitis—Capecitabine—esophageal cancer	0.00144	0.00177	CcSEcCtD
Methylphenidate—Urinary tract disorder—Capecitabine—esophageal cancer	0.00143	0.00176	CcSEcCtD
Methylphenidate—Connective tissue disorder—Capecitabine—esophageal cancer	0.00143	0.00175	CcSEcCtD
Methylphenidate—Urethral disorder—Capecitabine—esophageal cancer	0.00142	0.00175	CcSEcCtD
Methylphenidate—Breast disorder—Methotrexate—esophageal cancer	0.00141	0.00173	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—ABCC2—esophageal cancer	0.00141	0.00756	CbGpPWpGaD
Methylphenidate—Oedema—Cisplatin—esophageal cancer	0.0014	0.00172	CcSEcCtD
Methylphenidate—Anaphylactic shock—Cisplatin—esophageal cancer	0.0014	0.00172	CcSEcCtD
Methylphenidate—Visual impairment—Capecitabine—esophageal cancer	0.0014	0.00172	CcSEcCtD
Methylphenidate—Infection—Cisplatin—esophageal cancer	0.00139	0.00171	CcSEcCtD
Methylphenidate—CYP2D6—Melatonin metabolism and effects—CYP1B1—esophageal cancer	0.00137	0.00737	CbGpPWpGaD
Methylphenidate—Erythema multiforme—Capecitabine—esophageal cancer	0.00137	0.00169	CcSEcCtD
Methylphenidate—Nervous system disorder—Cisplatin—esophageal cancer	0.00137	0.00169	CcSEcCtD
Methylphenidate—Thrombocytopenia—Cisplatin—esophageal cancer	0.00137	0.00168	CcSEcCtD
Methylphenidate—Tachycardia—Cisplatin—esophageal cancer	0.00137	0.00168	CcSEcCtD
Methylphenidate—Skin disorder—Cisplatin—esophageal cancer	0.00136	0.00167	CcSEcCtD
Methylphenidate—Eye disorder—Capecitabine—esophageal cancer	0.00136	0.00167	CcSEcCtD
Methylphenidate—Hyperhidrosis—Cisplatin—esophageal cancer	0.00135	0.00166	CcSEcCtD
Methylphenidate—Asthma—Methotrexate—esophageal cancer	0.00135	0.00166	CcSEcCtD
Methylphenidate—Flushing—Capecitabine—esophageal cancer	0.00135	0.00166	CcSEcCtD
Methylphenidate—Cardiac disorder—Capecitabine—esophageal cancer	0.00135	0.00166	CcSEcCtD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00134	0.00717	CbGpPWpGaD
Methylphenidate—Anorexia—Cisplatin—esophageal cancer	0.00133	0.00164	CcSEcCtD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00133	0.00713	CbGpPWpGaD
Methylphenidate—Pancreatitis—Methotrexate—esophageal cancer	0.00132	0.00163	CcSEcCtD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00132	0.00708	CbGpPWpGaD
Methylphenidate—Angiopathy—Capecitabine—esophageal cancer	0.00132	0.00162	CcSEcCtD
Methylphenidate—Immune system disorder—Capecitabine—esophageal cancer	0.00131	0.00161	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—NFE2L2—esophageal cancer	0.00131	0.00703	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—CYP2A6—esophageal cancer	0.00131	0.00703	CbGpPWpGaD
Methylphenidate—Mediastinal disorder—Capecitabine—esophageal cancer	0.00131	0.00161	CcSEcCtD
Methylphenidate—Chills—Capecitabine—esophageal cancer	0.0013	0.0016	CcSEcCtD
Methylphenidate—Arrhythmia—Capecitabine—esophageal cancer	0.0013	0.00159	CcSEcCtD
Methylphenidate—Abdominal discomfort—Methotrexate—esophageal cancer	0.00129	0.00159	CcSEcCtD
Methylphenidate—Alopecia—Capecitabine—esophageal cancer	0.00128	0.00158	CcSEcCtD
Methylphenidate—Pancytopenia—Methotrexate—esophageal cancer	0.00128	0.00158	CcSEcCtD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.00128	0.00688	CbGpPWpGaD
Methylphenidate—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00127	0.00157	CcSEcCtD
Methylphenidate—Mental disorder—Capecitabine—esophageal cancer	0.00127	0.00156	CcSEcCtD
Methylphenidate—Erythema—Capecitabine—esophageal cancer	0.00126	0.00155	CcSEcCtD
Methylphenidate—Malnutrition—Capecitabine—esophageal cancer	0.00126	0.00155	CcSEcCtD
Methylphenidate—Paraesthesia—Cisplatin—esophageal cancer	0.00126	0.00154	CcSEcCtD
Methylphenidate—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00125	0.00154	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—ABCC2—esophageal cancer	0.00125	0.0067	CbGpPWpGaD
Methylphenidate—Dyspnoea—Cisplatin—esophageal cancer	0.00125	0.00153	CcSEcCtD
Methylphenidate—Erectile dysfunction—Methotrexate—esophageal cancer	0.00124	0.00153	CcSEcCtD
Methylphenidate—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00123	0.00151	CcSEcCtD
Methylphenidate—Back pain—Capecitabine—esophageal cancer	0.00122	0.0015	CcSEcCtD
Methylphenidate—Decreased appetite—Cisplatin—esophageal cancer	0.00122	0.00149	CcSEcCtD
Methylphenidate—Muscle spasms—Capecitabine—esophageal cancer	0.00121	0.00149	CcSEcCtD
Methylphenidate—Pneumonia—Methotrexate—esophageal cancer	0.00121	0.00149	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00121	0.00148	CcSEcCtD
Methylphenidate—Drowsiness—Methotrexate—esophageal cancer	0.0012	0.00148	CcSEcCtD
Methylphenidate—Infestation NOS—Methotrexate—esophageal cancer	0.0012	0.00148	CcSEcCtD
Methylphenidate—Infestation—Methotrexate—esophageal cancer	0.0012	0.00148	CcSEcCtD
Methylphenidate—Depression—Methotrexate—esophageal cancer	0.0012	0.00148	CcSEcCtD
Methylphenidate—Pain—Cisplatin—esophageal cancer	0.0012	0.00147	CcSEcCtD
Methylphenidate—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00119	0.00147	CcSEcCtD
Methylphenidate—Vision blurred—Capecitabine—esophageal cancer	0.00119	0.00146	CcSEcCtD
Methylphenidate—Tremor—Capecitabine—esophageal cancer	0.00118	0.00146	CcSEcCtD
Methylphenidate—Ill-defined disorder—Capecitabine—esophageal cancer	0.00117	0.00144	CcSEcCtD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.00117	0.00629	CbGpPWpGaD
Methylphenidate—Conjunctivitis—Methotrexate—esophageal cancer	0.00117	0.00144	CcSEcCtD
Methylphenidate—Anaemia—Capecitabine—esophageal cancer	0.00117	0.00144	CcSEcCtD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00117	0.00625	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—NFE2L2—esophageal cancer	0.00116	0.00623	CbGpPWpGaD
Methylphenidate—Sweating—Methotrexate—esophageal cancer	0.00115	0.00142	CcSEcCtD
Methylphenidate—Feeling abnormal—Cisplatin—esophageal cancer	0.00115	0.00142	CcSEcCtD
Methylphenidate—Haematuria—Methotrexate—esophageal cancer	0.00115	0.00141	CcSEcCtD
Methylphenidate—Malaise—Capecitabine—esophageal cancer	0.00114	0.0014	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00114	0.0014	CcSEcCtD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.00114	0.00609	CbGpPWpGaD
Methylphenidate—Epistaxis—Methotrexate—esophageal cancer	0.00114	0.0014	CcSEcCtD
Methylphenidate—Vertigo—Capecitabine—esophageal cancer	0.00114	0.0014	CcSEcCtD
Methylphenidate—Syncope—Capecitabine—esophageal cancer	0.00113	0.00139	CcSEcCtD
Methylphenidate—Leukopenia—Capecitabine—esophageal cancer	0.00113	0.00139	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—CYP2A6—esophageal cancer	0.00113	0.00605	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—SST—esophageal cancer	0.00112	0.00603	CbGpPWpGaD
Methylphenidate—Palpitations—Capecitabine—esophageal cancer	0.00112	0.00137	CcSEcCtD
Methylphenidate—Loss of consciousness—Capecitabine—esophageal cancer	0.00111	0.00137	CcSEcCtD
Methylphenidate—Body temperature increased—Cisplatin—esophageal cancer	0.00111	0.00136	CcSEcCtD
Methylphenidate—Cough—Capecitabine—esophageal cancer	0.0011	0.00136	CcSEcCtD
Methylphenidate—Hypertension—Capecitabine—esophageal cancer	0.00109	0.00134	CcSEcCtD
Methylphenidate—Haemoglobin—Methotrexate—esophageal cancer	0.00109	0.00133	CcSEcCtD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00108	0.00581	CbGpPWpGaD
Methylphenidate—Haemorrhage—Methotrexate—esophageal cancer	0.00108	0.00133	CcSEcCtD
Methylphenidate—Arthralgia—Capecitabine—esophageal cancer	0.00108	0.00132	CcSEcCtD
Methylphenidate—Myalgia—Capecitabine—esophageal cancer	0.00108	0.00132	CcSEcCtD
Methylphenidate—Chest pain—Capecitabine—esophageal cancer	0.00108	0.00132	CcSEcCtD
Methylphenidate—Pharyngitis—Methotrexate—esophageal cancer	0.00107	0.00132	CcSEcCtD
Methylphenidate—Anxiety—Capecitabine—esophageal cancer	0.00107	0.00132	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00107	0.00131	CcSEcCtD
Methylphenidate—Urinary tract disorder—Methotrexate—esophageal cancer	0.00107	0.00131	CcSEcCtD
Methylphenidate—Discomfort—Capecitabine—esophageal cancer	0.00106	0.00131	CcSEcCtD
Methylphenidate—Urethral disorder—Methotrexate—esophageal cancer	0.00106	0.0013	CcSEcCtD
Methylphenidate—Dry mouth—Capecitabine—esophageal cancer	0.00105	0.00129	CcSEcCtD
Methylphenidate—Visual impairment—Methotrexate—esophageal cancer	0.00104	0.00128	CcSEcCtD
Methylphenidate—Confusional state—Capecitabine—esophageal cancer	0.00104	0.00128	CcSEcCtD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.00104	0.00557	CbGpPWpGaD
Methylphenidate—Oedema—Capecitabine—esophageal cancer	0.00103	0.00127	CcSEcCtD
Methylphenidate—Hypersensitivity—Cisplatin—esophageal cancer	0.00103	0.00127	CcSEcCtD
Methylphenidate—Infection—Capecitabine—esophageal cancer	0.00102	0.00126	CcSEcCtD
Methylphenidate—Erythema multiforme—Methotrexate—esophageal cancer	0.00102	0.00126	CcSEcCtD
Methylphenidate—Shock—Capecitabine—esophageal cancer	0.00101	0.00125	CcSEcCtD
Methylphenidate—Nervous system disorder—Capecitabine—esophageal cancer	0.00101	0.00124	CcSEcCtD
Methylphenidate—Eye disorder—Methotrexate—esophageal cancer	0.00101	0.00124	CcSEcCtD
Methylphenidate—Thrombocytopenia—Capecitabine—esophageal cancer	0.00101	0.00124	CcSEcCtD
Methylphenidate—Tachycardia—Capecitabine—esophageal cancer	0.00101	0.00124	CcSEcCtD
Methylphenidate—Asthenia—Cisplatin—esophageal cancer	0.001	0.00123	CcSEcCtD
Methylphenidate—Cardiac disorder—Methotrexate—esophageal cancer	0.001	0.00123	CcSEcCtD
Methylphenidate—Skin disorder—Capecitabine—esophageal cancer	0.001	0.00123	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—CYP2A6—esophageal cancer	0.000998	0.00536	CbGpPWpGaD
Methylphenidate—Hyperhidrosis—Capecitabine—esophageal cancer	0.000997	0.00123	CcSEcCtD
Methylphenidate—Anorexia—Capecitabine—esophageal cancer	0.000983	0.00121	CcSEcCtD
Methylphenidate—Angiopathy—Methotrexate—esophageal cancer	0.00098	0.00121	CcSEcCtD
Methylphenidate—Immune system disorder—Methotrexate—esophageal cancer	0.000976	0.0012	CcSEcCtD
Methylphenidate—Mediastinal disorder—Methotrexate—esophageal cancer	0.000974	0.0012	CcSEcCtD
Methylphenidate—Chills—Methotrexate—esophageal cancer	0.00097	0.00119	CcSEcCtD
Methylphenidate—Diarrhoea—Cisplatin—esophageal cancer	0.000957	0.00118	CcSEcCtD
Methylphenidate—Alopecia—Methotrexate—esophageal cancer	0.000955	0.00117	CcSEcCtD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000953	0.00511	CbGpPWpGaD
Methylphenidate—Mental disorder—Methotrexate—esophageal cancer	0.000947	0.00116	CcSEcCtD
Methylphenidate—Malnutrition—Methotrexate—esophageal cancer	0.000941	0.00116	CcSEcCtD
Methylphenidate—Erythema—Methotrexate—esophageal cancer	0.000941	0.00116	CcSEcCtD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00094	0.00504	CbGpPWpGaD
Methylphenidate—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00094	0.00115	CcSEcCtD
Methylphenidate—Insomnia—Capecitabine—esophageal cancer	0.000933	0.00115	CcSEcCtD
Methylphenidate—Paraesthesia—Capecitabine—esophageal cancer	0.000926	0.00114	CcSEcCtD
Methylphenidate—Dyspnoea—Capecitabine—esophageal cancer	0.000919	0.00113	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—TGFBR2—esophageal cancer	0.000919	0.00493	CbGpPWpGaD
Methylphenidate—Back pain—Methotrexate—esophageal cancer	0.00091	0.00112	CcSEcCtD
Methylphenidate—Dyspepsia—Capecitabine—esophageal cancer	0.000908	0.00112	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—HMOX1—esophageal cancer	0.000906	0.00486	CbGpPWpGaD
Methylphenidate—Decreased appetite—Capecitabine—esophageal cancer	0.000896	0.0011	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—GHRL—esophageal cancer	0.000894	0.0048	CbGpPWpGaD
Methylphenidate—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00089	0.00109	CcSEcCtD
Methylphenidate—Vomiting—Cisplatin—esophageal cancer	0.00089	0.00109	CcSEcCtD
Methylphenidate—Fatigue—Capecitabine—esophageal cancer	0.000889	0.00109	CcSEcCtD
Methylphenidate—Vision blurred—Methotrexate—esophageal cancer	0.000887	0.00109	CcSEcCtD
Methylphenidate—Rash—Cisplatin—esophageal cancer	0.000882	0.00108	CcSEcCtD
Methylphenidate—Pain—Capecitabine—esophageal cancer	0.000882	0.00108	CcSEcCtD
Methylphenidate—Constipation—Capecitabine—esophageal cancer	0.000882	0.00108	CcSEcCtD
Methylphenidate—Dermatitis—Cisplatin—esophageal cancer	0.000881	0.00108	CcSEcCtD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.000881	0.00473	CbGpPWpGaD
Methylphenidate—Ill-defined disorder—Methotrexate—esophageal cancer	0.000873	0.00107	CcSEcCtD
Methylphenidate—Anaemia—Methotrexate—esophageal cancer	0.000869	0.00107	CcSEcCtD
Methylphenidate—Feeling abnormal—Capecitabine—esophageal cancer	0.00085	0.00104	CcSEcCtD
Methylphenidate—Malaise—Methotrexate—esophageal cancer	0.000848	0.00104	CcSEcCtD
Methylphenidate—Vertigo—Methotrexate—esophageal cancer	0.000845	0.00104	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000843	0.00104	CcSEcCtD
Methylphenidate—Leukopenia—Methotrexate—esophageal cancer	0.000842	0.00103	CcSEcCtD
Methylphenidate—Nausea—Cisplatin—esophageal cancer	0.000831	0.00102	CcSEcCtD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.000826	0.00443	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000821	0.00441	CbGpPWpGaD
Methylphenidate—Cough—Methotrexate—esophageal cancer	0.000821	0.00101	CcSEcCtD
Methylphenidate—Urticaria—Capecitabine—esophageal cancer	0.000819	0.00101	CcSEcCtD
Methylphenidate—Abdominal pain—Capecitabine—esophageal cancer	0.000815	0.001	CcSEcCtD
Methylphenidate—Body temperature increased—Capecitabine—esophageal cancer	0.000815	0.001	CcSEcCtD
Methylphenidate—Convulsion—Methotrexate—esophageal cancer	0.000815	0.001	CcSEcCtD
Methylphenidate—Myalgia—Methotrexate—esophageal cancer	0.000801	0.000984	CcSEcCtD
Methylphenidate—Arthralgia—Methotrexate—esophageal cancer	0.000801	0.000984	CcSEcCtD
Methylphenidate—Chest pain—Methotrexate—esophageal cancer	0.000801	0.000984	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000795	0.000978	CcSEcCtD
Methylphenidate—Discomfort—Methotrexate—esophageal cancer	0.000791	0.000973	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—TGFBR2—esophageal cancer	0.00079	0.00424	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—HMOX1—esophageal cancer	0.000779	0.00418	CbGpPWpGaD
Methylphenidate—Confusional state—Methotrexate—esophageal cancer	0.000774	0.000951	CcSEcCtD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000772	0.00414	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000768	0.00412	CbGpPWpGaD
Methylphenidate—Anaphylactic shock—Methotrexate—esophageal cancer	0.000768	0.000944	CcSEcCtD
Methylphenidate—Infection—Methotrexate—esophageal cancer	0.000763	0.000937	CcSEcCtD
Methylphenidate—Hypersensitivity—Capecitabine—esophageal cancer	0.00076	0.000934	CcSEcCtD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000758	0.00407	CbGpPWpGaD
Methylphenidate—Nervous system disorder—Methotrexate—esophageal cancer	0.000753	0.000925	CcSEcCtD
Methylphenidate—Thrombocytopenia—Methotrexate—esophageal cancer	0.000752	0.000924	CcSEcCtD
Methylphenidate—Skin disorder—Methotrexate—esophageal cancer	0.000746	0.000917	CcSEcCtD
Methylphenidate—Hyperhidrosis—Methotrexate—esophageal cancer	0.000742	0.000912	CcSEcCtD
Methylphenidate—Asthenia—Capecitabine—esophageal cancer	0.00074	0.000909	CcSEcCtD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000732	0.00393	CbGpPWpGaD
Methylphenidate—Anorexia—Methotrexate—esophageal cancer	0.000732	0.000899	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000731	0.00392	CbGpPWpGaD
Methylphenidate—Pruritus—Capecitabine—esophageal cancer	0.00073	0.000897	CcSEcCtD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000722	0.00387	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000712	0.00382	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—ADH7—esophageal cancer	0.000706	0.00379	CbGpPWpGaD
Methylphenidate—Diarrhoea—Capecitabine—esophageal cancer	0.000706	0.000867	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—TGFBR2—esophageal cancer	0.0007	0.00376	CbGpPWpGaD
Methylphenidate—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000699	0.00086	CcSEcCtD
Methylphenidate—Insomnia—Methotrexate—esophageal cancer	0.000694	0.000853	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—HMOX1—esophageal cancer	0.00069	0.0037	CbGpPWpGaD
Methylphenidate—Paraesthesia—Methotrexate—esophageal cancer	0.000689	0.000847	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000687	0.00369	CbGpPWpGaD
Methylphenidate—Dyspnoea—Methotrexate—esophageal cancer	0.000684	0.000841	CcSEcCtD
Methylphenidate—Somnolence—Methotrexate—esophageal cancer	0.000682	0.000839	CcSEcCtD
Methylphenidate—Dizziness—Capecitabine—esophageal cancer	0.000682	0.000838	CcSEcCtD
Methylphenidate—Dyspepsia—Methotrexate—esophageal cancer	0.000676	0.000831	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.000675	0.00362	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—GNG7—esophageal cancer	0.000675	0.00362	CbGpPWpGaD
Methylphenidate—Decreased appetite—Methotrexate—esophageal cancer	0.000667	0.00082	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000663	0.000815	CcSEcCtD
Methylphenidate—Fatigue—Methotrexate—esophageal cancer	0.000662	0.000814	CcSEcCtD
Methylphenidate—Pain—Methotrexate—esophageal cancer	0.000656	0.000807	CcSEcCtD
Methylphenidate—Vomiting—Capecitabine—esophageal cancer	0.000656	0.000806	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000651	0.00349	CbGpPWpGaD
Methylphenidate—Rash—Capecitabine—esophageal cancer	0.00065	0.000799	CcSEcCtD
Methylphenidate—Dermatitis—Capecitabine—esophageal cancer	0.00065	0.000798	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000647	0.00347	CbGpPWpGaD
Methylphenidate—Headache—Capecitabine—esophageal cancer	0.000646	0.000794	CcSEcCtD
Methylphenidate—Feeling abnormal—Methotrexate—esophageal cancer	0.000633	0.000778	CcSEcCtD
Methylphenidate—SLC6A3—Neuronal System—ALDH2—esophageal cancer	0.000633	0.00339	CbGpPWpGaD
Methylphenidate—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000628	0.000772	CcSEcCtD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000622	0.00334	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000621	0.00333	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—ADH1B—esophageal cancer	0.000619	0.00332	CbGpPWpGaD
Methylphenidate—Nausea—Capecitabine—esophageal cancer	0.000613	0.000753	CcSEcCtD
Methylphenidate—Urticaria—Methotrexate—esophageal cancer	0.00061	0.00075	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000609	0.00327	CbGpPWpGaD
Methylphenidate—Abdominal pain—Methotrexate—esophageal cancer	0.000607	0.000746	CcSEcCtD
Methylphenidate—Body temperature increased—Methotrexate—esophageal cancer	0.000607	0.000746	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000596	0.0032	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000596	0.0032	CbGpPWpGaD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000585	0.00314	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000577	0.0031	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP26A1—esophageal cancer	0.000576	0.00309	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000568	0.00305	CbGpPWpGaD
Methylphenidate—Hypersensitivity—Methotrexate—esophageal cancer	0.000566	0.000695	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000551	0.00296	CbGpPWpGaD
Methylphenidate—Asthenia—Methotrexate—esophageal cancer	0.000551	0.000677	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.00055	0.00295	CbGpPWpGaD
Methylphenidate—Pruritus—Methotrexate—esophageal cancer	0.000543	0.000668	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—GSTO1—esophageal cancer	0.000535	0.00287	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTO1—esophageal cancer	0.000528	0.00283	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000528	0.00283	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000528	0.00283	CbGpPWpGaD
Methylphenidate—Diarrhoea—Methotrexate—esophageal cancer	0.000525	0.000646	CcSEcCtD
Methylphenidate—Dizziness—Methotrexate—esophageal cancer	0.000508	0.000624	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—NOS2—esophageal cancer	0.000501	0.00269	CbGpPWpGaD
Methylphenidate—Vomiting—Methotrexate—esophageal cancer	0.000488	0.0006	CcSEcCtD
Methylphenidate—Rash—Methotrexate—esophageal cancer	0.000484	0.000595	CcSEcCtD
Methylphenidate—Dermatitis—Methotrexate—esophageal cancer	0.000484	0.000594	CcSEcCtD
Methylphenidate—Headache—Methotrexate—esophageal cancer	0.000481	0.000591	CcSEcCtD
Methylphenidate—Nausea—Methotrexate—esophageal cancer	0.000456	0.00056	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000452	0.00242	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—ALDH2—esophageal cancer	0.000436	0.00234	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTT1—esophageal cancer	0.000415	0.00223	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP2A6—esophageal cancer	0.00041	0.0022	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.00041	0.0022	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.0004	0.00215	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—PTGS1—esophageal cancer	0.000389	0.00209	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000376	0.00201	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000363	0.00195	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP1B1—esophageal cancer	0.000331	0.00177	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000326	0.00175	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP19A1—esophageal cancer	0.000311	0.00167	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—EP300—esophageal cancer	0.000307	0.00164	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000307	0.00164	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.00025	0.00134	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.00024	0.00129	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000221	0.00119	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—TP53—esophageal cancer	0.000219	0.00118	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000212	0.00114	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.000167	0.000896	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.000167	0.000896	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.00016	0.000859	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CA1—esophageal cancer	0.000142	0.000762	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000142	0.000762	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000142	0.000761	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CA2—esophageal cancer	0.00013	0.000697	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000121	0.000648	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000121	0.000648	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.000106	0.000568	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—TYMP—esophageal cancer	0.000101	0.000543	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP26A1—esophageal cancer	9.85e-05	0.000528	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ALOX15—esophageal cancer	9.59e-05	0.000515	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—TPI1—esophageal cancer	9.15e-05	0.000491	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTO1—esophageal cancer	9.15e-05	0.000491	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ALDOB—esophageal cancer	8.78e-05	0.000471	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GAPDH—esophageal cancer	8.45e-05	0.000453	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CRABP1—esophageal cancer	8.37e-05	0.000449	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GNG7—esophageal cancer	7.96e-05	0.000427	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ALDH2—esophageal cancer	7.46e-05	0.0004	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTT1—esophageal cancer	7.1e-05	0.000381	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP2A6—esophageal cancer	7.02e-05	0.000376	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ENO1—esophageal cancer	6.65e-05	0.000357	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTGS1—esophageal cancer	6.65e-05	0.000357	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PSME1—esophageal cancer	6.55e-05	0.000352	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PSME2—esophageal cancer	6.55e-05	0.000352	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP1B1—esophageal cancer	5.65e-05	0.000303	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP19A1—esophageal cancer	5.32e-05	0.000285	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HMOX1—esophageal cancer	4.85e-05	0.00026	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ABCB1—esophageal cancer	4.66e-05	0.00025	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CREBBP—esophageal cancer	3.11e-05	0.000167	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NOS3—esophageal cancer	2.79e-05	0.000149	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTGS2—esophageal cancer	2.55e-05	0.000137	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—EP300—esophageal cancer	2.12e-05	0.000114	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.57e-05	8.41e-05	CbGpPWpGaD
